Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.
Actively Recruiting
Researchers are evaluating the efficacy and safety of NIO752 in people with Progressive Supranuclear Palsy PSP in this Phase III randomized, placebo-controlled study. The trial aims to understand how well NIO752 works in treating PSP Richardson syndrome, a condition characterized by certain neurological symptoms with onset less than 5 years ago. Participants with mild to moderate PSP and specific functional abilities are included to assess the treatments impact. Participants will be randomly assigned in a 21 ratio to receive either NIO752, an antisense oligonucleotide solution, or a placebo solution. This double-blind treatment phase is followed by an open-label extension where all participants can continue receiving NIO752. The study measures changes in disease severity and function over 72 weeks using several scales and cognitive tests. During the study, participants and their reliable study partners will attend visits for assessments including neurological exams, cognitive tests, and brain MRI scans. Researchers will monitor changes in PSP rating scales, daily living activities, cognitive function, and relevant biomarkers in cerebrospinal fluid. Safety is closely tracked through adverse event reporting. The total study duration includes 72 weeks of treatment followed by long-term monitoring until study completion.
Actively Recruiting
Parkinsons disease PD is a neurological disorder that worsens over time with symptoms like tremors, stiffness, and slow movement. This research evaluates how effective foscarbidopafoslevodopa is for German adults in the early stages of advanced PD. Approximately 125 adults prescribed this treatment by their physicians will participate in this observational study. Participants will receive foslevodopafoscarbidopa through subcutaneous infusion as directed by their doctors, following routine clinical practice. The study includes a follow-up period lasting up to 12 months to monitor treatment effects without adding extra burden to participants. During the study, participants will attend regular hospital or clinic visits as part of their usual care. Researchers will measure changes in OFF time hours up to 6 months to assess motor symptom improvements. The study will also look at quality of life and psychosocial functioning while monitoring participants throughout the year-long observation period.
Actively Recruiting
This research aims to systematically record the results of routine laryngeal examinations and specific swallowing difficulties in patients with various neurodegenerative diseases such as Multiple System Atrophy MSA, Progressive Supranuclear Palsy PSP, Parkinsons Disease, Motor Neuron Disease MND, and other related conditions. These disorders often lead to swallowing problems known as dysphagia, which can cause serious complications like dehydration, malnutrition, and pneumonia. The study seeks to better understand how these swallowing issues vary with different disease types and stages. Participants undergo a fiberoptic or flexible endoscopic evaluation of swallowing FEES using a structured task protocol designed to assess laryngopharyngeal function. When available, laryngeal electromyography EMG results are also collected. The study includes patients diagnosed according to established diagnostic criteria for their specific neurodegenerative disorder. Data collected also include demographic information and disease-specific details, along with responses to two questionnaires assessing swallowing disturbances and quality of life related to swallowing. During the study, participants will have their swallowing function assessed through FEES and complete questionnaires about their swallowing difficulties and quality of life. Researchers will evaluate laryngeal movement disorders and dysphagia as primary outcomes. This observational study does not involve any treatment intervention and aims to follow participants over time to categorize swallowing issues and correlate them with their disease subtype. The study has been ongoing since 2017 and plans to continue recruitment and data collection through 2028.